Trodelvy (Sacituzumab govitecan-hziy)
- Medicine Name: Trodelvy
- Generic Name: Sacituzumab Govitecan-hziy
- Dosage Form & Strength: For injection: 200 mg , 180 mg lyophilized powder in a single-dose vial
- Manufactured By: Gilead Sciences, Inc.
Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate used to treat adult patients with:
- metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.
- locally advanced/metastatic urothelial cancer (mUC) who have previously treated with a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
The recommended dose is 10 mg/kg weekly on Days 1 and 8 of each 21-day cycle, or until disease progression or unacceptable toxicity occurs. One should avoid substituting or combining Trodelvy with other irinotecan-containing medications. Administer only as an intravenous infusion, not as a bolus. Pre-infusion medicine and close monitoring are recommended, as well as necessary treatment changes to manage side effects.
- Sacituzumab Govitecan-hziy can cause severe or life-threatening neutropenia. Withhold it for absolute neutrophil count below 1500/mm3 on Day 1’st of any cycle or neutrophil count below 1000/mm3 on Day 8’th of any cycle. Withhold it for neutropenic fever.
- Trodelvy breast cancer drug can cause severe diarrhea. Withhold it for Grade 3-4 diarrhea at the juncture of scheduled treatment administration and resume when resolved to ≤ Grade 1.
- Sacituzumab Govitecan-hziy can cause severe and life-threatening hypersensitivity. Pre-infusion drug for patients receiving sacituzumab govitecan hziy is recommended. Observe patients precisely for infusion-related reactions during each infusion and for at least 30 minutes following completion of each infusion.
- Patients who are homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at greater risk for neutropenia and may be at greater risk for other adverse reactions following starting of trodelvy 180 mg treatment.
- Precisely assess patients with reduced UGT1A1 activity for the severe neutropenia. The apt dose for patients who are homozygous for UGT1A1*28 is not specified and should be considered based on the tolerance to treatment.
- Mechanism of action suggest that the trodelvy therapy can be responsible for causing teratogenicity and/or embryo-fetal lethality in case administered to a pregnant woman.
What documents are required to import Trodelvy?
Trodelvy (Sacituzumab govitecan-hziy) injection can be imported by patients or government hospitals on behalf of patients. The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of the respective country).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is Trodelvy available worldwide?
Trodelvy (Sacituzumab govitecan-hziy) injection is a prescription pharmaceutical drug that legally requires a medical prescription for dispensation.
Indian Pharma Network (IPN) facilitates the import of critical medications like Trodelvy globally, ensuring the named patient supply (NPS). IPN is the facilitator that provides essential support for:
- Availability of Trodelvy (Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka).
- Trodelvy available in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc
- Determining Medicine Price.
- Sourcing genuine and reliable sources from the USA, Canada, Europe, and Australia.
- Ensuring 100% transparency.
Trodelvy can be made available to patients, doctors, and hospitals in various countries across the globe. The order will be confirmed only after receiving a valid prescription from the doctor and, if required, an import permit.
Indian Pharma Network (IPN) can facilitate the supply of Trodelvy (prescription medicine) to locations worldwide while adhering to legal requirements (if applicable).
We assure quality and worldwide delivery as per the buyer’s specifications.
Indian Pharma Network is proficient in sourcing Trodelvy from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide in countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.
Indian Pharma Network (IPN) is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address. Your health and well-being are our top priorities
What is the Generic Name for the trade name drug Trodelvy®?
Is Trodelvy® approved by the FDA?
What is Trodelvy®?
What is the dosage and form of Trodelvy® supplied?
What are the most common side effects due to Trodelvy®?
How much does Trodelvy® cost in India?
What are the storage conditions of Trodelvy®?
How long is treatment with Trodelvy?
Is Trodelvy a chemo?
How many cycles of Trodelvy ?
Who is eligible for Trodelvy ?
What is the success rate of Sacituzumab?
Is trodelvy available in Asia?
How can I get Trodelvy injection?
Will I lose my hair on Trodelvy ?
Where is Trodelvy available in India?
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.